SeraCare Life Sciences Inc said it will be bought by an affiliate of private equity firm Linden Capital Partners for $80.8 million. The $4.00-per-share deal represents a premium of nearly 12 percent to SeraCare's Friday's close on the Nasdaq. SeraCare had 20.2 million shares outstanding as of Feb. 3.SeraCare, which supplies diagnostic control products for HIV, plasma-derived reagents and contract research services, had said last year it was exploring strategic alternatives, including a possible sale, after it received an unsolicited takeover offer from private equity firm MSMB Capital.The deal is expected to close in the second quarter if approved by shareholders, SeraCare said in a statement on Monday.
SeraCare Life Sciences, Inc. (SeraCare) serves the global life sciences industry by providing products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. Shares of SRLS remained unchanged at $3.58. In the past year, the shares have traded as low as $2.58 and as high as $4.48. On average, 27024 shares of SRLS exchange hands on a given day and today's volume is recorded at 0.
Source
